STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1805 by analyst upside · 2026-06-27
ACH
Accendra Health, Inc.
Healthcare · Market Cap $256M · P/E 0x
ANALYST PRICE TARGET
+34.4%
implied upside to consensus target
Current Price $3.34
Consensus Target $4.49
Bull Target $6.0
Bear Target $2.7
Analysts Covering 5
ANALYST CONSENSUS — HOLD
Strong Buy
0
Buy
2
Hold
2
Sell
1
52-Week Low $1.84
52-Week High $9.55
YTD Return +44.0%
FUNDAMENTALS
Market Cap $256M
P/E Ratio (TTM) N/A
Forward P/E 4.9x
EPS (TTM) $-1.44
PEG Ratio 0.70
Dividend Yield N/A
Revenue (TTM) $2.7B
Profit Margin -39.8%
52-WEEK RANGE
52-Week Low $1.84
52-Week High $9.55
Current Price $3.34
Bear Target $2.7
Bull Target $6.0
● Now $3.34 ● Target $4.49
TRADING DATA
Avg Volume 813K
YTD Return +44.0%
Analyst Count 5
Consensus Hold
Upside to Target +34.4%
Last Updated 2026-06-27

ANALYST SUMMARY

Accendra Health, Inc. (ACH) is currently trading at $3.34 with a Wall Street consensus price target of $4.49, implying potential upside of 34.4% over the next 12 months. 5 analysts currently cover ACH, with a consensus rating of Hold — 40% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $6.0, while the most cautious has a target of $2.7.

ACH operates in the Healthcare sector with a market capitalisation of $256M. The stock is up 44.0% year-to-date and is currently trading near the lower end of its 52-week range of $1.84 – $9.55.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ACH, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS — Reiterated
Neutral → Neutral 2026-05-12 33% win rate (6 calls)
Citigroup — Reiterated
Buy → Buy 2026-05-12 Building track record
Baird — Reiterated
Outperform → Outperform 2026-05-12 Building track record
Leerink Partners — Reiterated
Market Perform → Market Perform 2026-02-20 29% win rate (7 calls)
Citigroup — Reiterated
Buy → Buy 2026-01-09 Building track record
UBS ↓ Downgrade
Buy → Neutral 2025-11-03 33% win rate (6 calls)
JP Morgan — Reiterated
Underweight → Underweight 2025-08-27 43% win rate (7 calls)
UBS — Reiterated
Buy → Buy 2025-08-13 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →